ImmunityBio, Inc. (IBRX) - Stock Analysis
Last updated: Apr 25, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
ImmunityBio posted ~700% YoY product-revenue growth, secured EU conditional approval and Saudi accelerated approval, and has multiple imminent clinical/label catalysts plus an investor update on 2026-03-03; the share price has climbed ~66% over 21 days and trades well above its 21âday SMA, positioning it as a highârisk but potent short-term momentum play.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠High Cash Burn ⢠Negative Equity IBRX has strong liquidity and gross margins, but heavy debt, negative equity, persistent losses, and ongoing cash burn make it a high-risk, externally funded story.
Price Behavior
Key Price Behavior Insights: ⢠Downtrend Pressure ⢠Strong Support ⢠Key Resistance Support Level: $7.0â$7.3 Resistance Level: $8.1â$8.2 IBRX has weakened over the last month with a clear downtrend, holding near $7.0â$7.3 support but facing repeated rejection around $8.1â$8.2, so a break below $7.0 would be bearish while a reclaim of $8.2 would signal recovery.
Sentiment & News
Key News Insights: ⢠Revenue surge ⢠Legal overhang ⢠Commercial momentum IBRX is seeing a sharp revenue rebound and improving commercial momentum, but repeated shareholder litigation notices continue to create a significant legal overhang.
AI Summary
IBRX has moved from a purely speculative biotech to a real commercial story as ANKTIVA revenue scales, but the investment now hinges on whether that growth can outpace heavy cash burn, negative equity, and legal/FDA overhangs before dilution or regulatory risk caps the upside.
Description
ImmunityBio, Inc. is a clinical-stage biotechnology company developing therapies and vaccines targeting cancers and infectious diseases. The company applies multiple immunotherapy and cell therapy approachesâincluding engineered cytokine fusion proteins, synthetic immunomodulators, and both natural killer and T-cell platformsâand has candidates in Phase II/III trials for solid and liquid tumors (for example, bladder, pancreatic and lung cancers) as well as antiviral programs for pathogens such as SARS-CoV-2 and HIV. It maintains research collaborations and licensing arrangements with U.S. government institutes and several biopharma partners and is headquartered in San Diego, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 2 | Mar 9 | IBRX | ImmunityBio, Inc. | ImmunityBio posted ~700% YoY product-revenue growth, secured EU conditional approval and Saudi accelerated approval, and has multiple imminent clinical/label catalysts plus an investor update on 2026-03-03; the share price has climbed ~66% over 21 days and trades well above its 21âday SMA, positioning it as a highârisk but potent short-term momentum play. | Closed | -19.1% |
| Feb 19 | Feb 26 | IBRX | ImmunityBio, Inc. | Multiple recent regulatory wins (EU conditional approval for ANKTIVA+BCG on 2026-02-18, Saudi approval, FDA Type B meeting) plus an EU commercialization deal and accelerating product revenue (~$38M quarter) have driven a >200% month-long rally; momentum remains strong into further catalyst and financing headlines despite high risk. | Closed | +10.9% |
| Jan 16 | Jan 23 | IBRX | ImmunityBio, Inc. | ImmunityBio is a hot idea driven by accelerating commercial revenue growth (700% annual increase in 2025), regulatory approvals expanding markets, positive clinical data mid-January 2026, nearly doubled stock price in past month, despite ongoing financial risks. | Closed | +16.9% |